Dolutegravir/lamivudine/tenofovir
| Combination of | |
|---|---|
| Dolutegravir | Integrase strand transfer inhibitor |
| Lamivudine | Nucleoside reverse transcriptase inhibitor |
| Tenofovir disoproxil | Nucleoside reverse transcriptase inhibitor |
| Clinical data | |
| Other names | Tenofovir/lamivudine/dolutegravir (TLD) |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
Dolutegravir/lamivudine/tenofovir (DTG/3TC/TDF) is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS.[2] It is a combination of dolutegravir, lamivudine, and tenofovir disoproxil.[2] As of 2019, it is listed by the World Health Organization (WHO) as the first line treatment for adults, with tenofovir/lamivudine/efavirenz as an alternative.[3] It is taken by mouth.[4]
Side effects may include trouble sleeping, weight gain, and rash.[3][4] While there are concerns that use during pregnancy results in a 0.2% increased risk of neural tube defects in the baby, this does not rule out its use.[3] Use remains recommended after the first trimester.[3] Use is not recommended in those with kidney problems.[4] The combination is a type of antiretroviral therapy.[3]
It is on the World Health Organization's List of Essential Medicines.[5] In some countries it is available as a generic medication.[6] It was approved for medical use in the United States in May 2026.[1]
Medical uses
As of 2019, it is listed by the World Health Organization (WHO) as the first-line treatment for adults with HIV/AIDS, with tenofovir/lamivudine/efavirenz as an alternative.[3] It may be used in people with both HIV and tuberculosis, however if the person is on rifampicin a larger dose of dolutegravir is needed.[3]
Side effects
Side effects may include trouble sleeping and weight gain.[3] While there are concerns that use during pregnancy results in a 0.2% increased risk of neural tube defects in the baby, this does not rule out its use.[3] Use remains recommended after the first trimester.[3] It should not be used with dofetilide.[4]
Society and culture
Economics
In the developing world it costs about US$75 per year.[7] It is considered more cost effective than tenofovir/lamivudine/efavirenz as of 2019.[3]
References
- 1 2 "Approval Label" (PDF). Accessdata.fda.gov. Retrieved 2 August 2026.
- 1 2 "Dolutegravir (DTG) and the fixed dose combination (FDC) of tenofovir/lamivudine/dolutegravir (TLD)" (PDF). World Health Organization (WHO). Retrieved 15 November 2019.
- 1 2 3 4 5 6 7 8 9 10 11 "Policy brief: update of recommendations on first- and second-line antiretroviral regimens" (Document). World Health Organization. 2019. hdl:10665/325892. WHO/CDS/HIV/19.15; License: CC BY-NC-SA 3.0 IGO.
- 1 2 3 4 "WHO-PQ Recommended summary of product characteristics" (PDF). July 2019. Archived from the original (PDF) on 16 November 2019. Retrieved 16 November 2019.
- ↑ World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. 2019. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ↑ "TDF/3TC/DTG" (PDF). Retrieved 16 November 2019.
- ↑ Vitoria M, Hill A, Ford N, Doherty M, Clayden P, Venter F, et al. (July 2018). "The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?". AIDS. 32 (12): 1551–1561. doi:10.1097/QAD.0000000000001845. PMID 29746295. S2CID 13674631.
{{cite journal}}: CS1 maint: overridden setting (link)